Therapeutic Vaccines Market Report: Size, Share and Outlook by 2031

The therapeutic vaccines market is anticipated to expand significantly, with projections indicating an increase from US$ 1,244.94 million in 2024 to US$ 2,934.57 million by 2031. This growth trajectory suggests a compound annual growth rate (CAGR) of 13.0% from 2024 to 2031. Key drivers of this market expansion include the rising incidence of chronic diseases and a surge in investments and funding directed towards vaccine development. However, the growth of the therapeutic vaccines market faces challenges, particularly from regulatory hurdles.

Traditional technologies are inadequate for developing vaccines against emerging pathogens that could lead to pandemics. Therefore, it is crucial to create platforms capable of swiftly responding to pandemic threats and effectively adapting to measures addressing new variants. Innovative vaccine platforms, such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines, are transforming the landscape of therapeutic vaccine development. The transition towards more efficient and customizable vaccine technologies has facilitated the creation of vaccines targeting a variety of diseases, including cancers, autoimmune disorders, and infectious diseases. The success of mRNA technology in COVID-19 vaccines highlights its potential for therapeutic applications beyond infectious diseases, extending into areas like cancer and chronic infections. These advanced platforms enable faster, more adaptable, and scalable vaccine production, thereby accelerating the introduction of new therapeutic vaccines.

Researchers are actively working on innovative platforms for future applications. For example, a team at the Wyss Institute at Harvard University is pioneering a vaccine platform called OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to develop safe and effective therapeutic and prophylactic vaccines against both viral and bacterial infections. Upon administration, OMNIVAX vaccines create a scaffold that attracts dendritic immune cells, programming them to target specific antigens. These cells are subsequently released and migrate to nearby lymph nodes, where they trigger a systemic and prolonged immune response. The modular nature of this technology allows for the incorporation of multiple antigens into a single OMNIVAX vaccine. Such advancements in vaccine technology are expected to introduce new trends in the therapeutic vaccines market in the near future.

End User-Based Insights

The therapeutic vaccines market is categorized based on end users into hospitals, clinics, and other facilities. In 2024, the hospitals segment is projected to hold the largest share of the therapeutic vaccines market. Therapeutic vaccines are increasingly recognized as essential components in the treatment of cancer and other chronic diseases, which are often managed within hospital environments. Hospitals possess the advanced infrastructure necessary for administering specialized therapies targeting cancer and autoimmune diseases. As the global prevalence of chronic diseases, particularly cancer, continues to rise, hospitals are expected to maintain a steady demand for these treatments. They provide comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are vital for patients receiving therapeutic vaccine treatments. Furthermore, an increase in hospital-based research and clinical trials is contributing to the growth of the therapeutic vaccines market within this segment. Many therapeutic vaccines are tested in hospital settings, allowing healthcare professionals to remain informed about the latest developments in vaccines and treatments, thereby driving the growth of the therapeutic vaccines market.

In preparing the therapeutic vaccines market report, various primary and secondary sources were utilized, including the World Health Organization (WHO), Global Cancer Facts & Figures, and the American Cancer Society.